Aimmune Therapeutics
AIMT
AIMT was delisted on the 12th of October, 2020.
92 hedge funds and large institutions have $676M invested in Aimmune Therapeutics in 2016 Q4 according to their latest regulatory filings, with 23 funds opening new positions, 36 increasing their positions, 18 reducing their positions, and 5 closing their positions.
360% more first-time investments, than exits
New positions opened: 23 | Existing positions closed: 5
230% more call options, than puts
Call options by funds: $684K | Put options by funds: $207K
100% more repeat investments, than reductions
Existing positions increased: 36 | Existing positions reduced: 18
49% more capital invested
Capital invested by funds: $454M → $676M (+$222M)
24% more funds holding
Funds holding: 74 → 92 (+18)
0% more funds holding in top 10
Funds holding in top 10: 5 → 5 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$14.2M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
+$8.33M |
| 3 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
+$6.72M |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
+$6.39M |
| 5 |
EA
Emerald Advisers
Leola,
Pennsylvania
|
+$6.31M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$12.6M |
| 2 |
TG
TLP Group
Evanston,
Illinois
|
-$8.92M |
| 3 |
FCMI
Foresite Capital Management II
Larkspur,
California
|
-$2.7M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$1.56M |
| 5 |
CCI
Columbus Circle Investors
|
-$918K |
AIMT Hedge Fund Activity: Q4 2016 in Review
92 of the 4,008 institutional investors tracked by Wall St. Rank reported a position in Aimmune Therapeutics (AIMT) for Q4 2016, worth a combined $676M — up 49% from $454M a quarter earlier.
Buyers outnumbered sellers: 23 funds opened new AIMT positions and 5 closed out — a net gain of 18 holders — while 36 added to existing stakes and 18 trimmed.
The largest buyer was BlackRock Fund Advisors, adding an estimated $14.2M. The largest seller was RA Capital Management, cutting an estimated $12.6M.
- 92 institutional investors held Aimmune Therapeutics (AIMT) as of Q4 2016, up from 74 in Q3 2016.
- Funds reported $676M of Aimmune Therapeutics stock for Q4 2016, up 49% quarter-over-quarter.
- 23 funds opened new Aimmune Therapeutics positions in Q4 2016 and 5 closed out, a net change of +18 holders.
- The largest Aimmune Therapeutics buyer in Q4 2016 was BlackRock Fund Advisors, an estimated $14.2M added.
- The largest Aimmune Therapeutics seller in Q4 2016 was RA Capital Management, an estimated $12.6M sold.
Based on aggregated 13F filings for Q4 2016.